Oral and intravenous fosfomycin in complicated urinary tract infections

Area of Science:

• Infectious Diseases
• Pharmacology
• Urology

Background:

• Urinary tract infections (UTIs) are a common health issue, straining healthcare resources.
• Increasing antibiotic resistance, including quinolone, β-lactamase, and carbapenemase resistance, complicates treatment.
• Multidrug-resistant uropathogens pose a significant global health challenge.

Purpose of the Study:

• To evaluate the role and efficacy of fosfomycin as an alternative therapy for UTIs.
• To highlight fosfomycin's activity against multidrug-resistant (MDR) Gram-positive and Gram-negative bacteria.
• To review current clinical experience with fosfomycin in complicated UTIs and special populations.

Main Methods:

• Review of existing clinical data and studies on fosfomycin use in UTIs.
• Analysis of fosfomycin's antimicrobial spectrum against resistant uropathogens.
• Examination of clinical experience in patients with MDR bacteria, recurrent UTIs, and kidney transplants.

Main Results:

• Fosfomycin demonstrates broad-spectrum activity against MDR microorganisms.
• Clinical experience is growing for fosfomycin in complicated UTIs, including those caused by resistant bacteria.
• Fosfomycin is emerging as a viable option for recurrent UTIs and in special patient groups.

Conclusions:

• Fosfomycin is a promising alternative therapy for complicated urinary tract infections (cUTIs) in the era of multidrug resistance.
• Increased clinical experience and ongoing studies are supporting fosfomycin's role in managing resistant UTIs.
• Further research is required to fully establish fosfomycin's efficacy and optimal use in cUTIs.